Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older ...
Survival results for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy Trial previously met the dual primary ...
Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, HER2-negative metastatic breast cancer. Phase 2 results reveal median ...
Datopotamab deruxtecan-dlnk significantly improves progression-free survival in HR-positive, HER2-negative breast cancer compared with chemotherapy. The TROPION-Breast01 trial showed a higher ...
Vepdegestrant significantly improved progression-free survival in ESR1-mutant ER-positive, HER2-negative advanced breast cancer compared to Faslodex, with a median of 5.0 months versus 2.1 months. The ...
This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which ...
WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results